Technology area: Biotechnology & Pharmaceuticals
6 pending office actions • 4 art units • 6 examiners • 0 of 6 (0%) have an AI response strategy ready • 3 patents granted in the last 365 days
Teva Pharmaceuticals USA Inc. has 6 pending office actions in Biotechnology & Pharmaceuticals. The actions are distributed among 6 examiners and 4 art units, showing multiple examiner assignments within a smaller set of technical groups.
DAVIS, BRIAN J is the listed busiest examiner, with 1 pending matter. No examiner accounts for a repeated share of the listed workload, so portfolio oversight should center on application-specific deadlines, objections, and response plans.
The four-art-unit structure provides an opportunity to compare related pharmaceutical issues across examination groups. Counsel can coordinate recurring claim and disclosure positions, but should tailor arguments to the assigned examiner and art unit. A consolidated docket and issue matrix would help preserve consistency without treating the actions as a single prosecution matter.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (17%) |
| §103 only | 2 (33%) |
| Double-patenting only | 1 (17%) |
| Double-patenting + other | 1 (17%) |
| Multi-statute (no §101) | 1 (17%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DAVIS, BRIAN J | 1 | 84.8% | -3.9% |
| RAO, SAVITHA M | 1 | 60.7% | +29.7% |
| LEE, ANDREW P | 1 | 48.5% | +22.8% |
| FAY, ZOHREH ALEMZADEH | 1 | 52.1% | -6.2% |
| LIU, TRACY | 1 | 54.5% | +26.9% |
| WAX, ROBERT A | 1 | 25.7% | +3.9% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18919039 | NOVEL PHARMACEUTICAL FORMULATIONS | DAVIS, BRIAN J | — |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18245565 | MULTIPARTICULATE DOSAGE FORMS COMPRISING DEUTETRABENAZINE | WAX, ROBERT A | 19d overdue |
| 18769264 | BENZOQUINOLONE INHIBITORS OF VMAT2 | RAO, SAVITHA M | — |
| 18677401 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | LEE, ANDREW P | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18402393 | Formulations and Pharmacokinetics of Deuterated Benzoquinoline Inhibitors of Vesicular Monoamine Transporter 2 | LIU, TRACY | 42d overdue |
| 18769264 | BENZOQUINOLONE INHIBITORS OF VMAT2 | RAO, SAVITHA M | — |
| 18677401 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | LEE, ANDREW P | — |
| Art Unit | Apps |
|---|---|
| 1614 | 2 |
| 1691 | 2 |
| 1617 | 1 |
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18919039 | NOVEL PHARMACEUTICAL FORMULATIONS | DAVIS, BRIAN J | 1614 | §102DP | Non-Final OA | — | Pending | Oct 17, 2024 |
| 18769264 | BENZOQUINOLONE INHIBITORS OF VMAT2 | RAO, SAVITHA M | 1691 | §102§103§112 | Non-Final OA | — | Pending | Jul 10, 2024 |
| 18677401 | METHODS FOR THE TREATMENT OF ABNORMAL INVOLUNTARY MOVEMENT DISORDERS | LEE, ANDREW P | 1691 | §101§112DP | Non-Final OA | — | Pending | May 29, 2024 |
| 18692074 | MULTIPARTICULATE DOSAGE FORMS COMPRISING DEUTETRABENAZINE | FAY, ZOHREH ALEMZADEH | 1617 | §103 | Non-Final OA | — | Pending | Mar 14, 2024 |
| 18402393 | Formulations and Pharmacokinetics of Deuterated Benzoquinoline Inhibitors of Vesicular Monoamine Transporter 2 | LIU, TRACY | 1614 | DP | Final Rejection | 42d overdue | Pending | Jan 02, 2024 |
| 18245565 | MULTIPARTICULATE DOSAGE FORMS COMPRISING DEUTETRABENAZINE | WAX, ROBERT A | 1615 | §103 | Final Rejection | 19d overdue | Pending | Mar 16, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTeva Pharmaceuticals USA Inc. has 6 pending office actions as of October 2026, spread across 4 art units and 6 examiners.
Brian J Davis has the most, with 1 of Teva Pharmaceuticals USA Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
